| patupilone (EPO 906) / Novartis |
NCT00005807: Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer |
|
|
| Completed | 1 | 40 | US | BMS-247550, epothilone derivative | Albert Einstein College of Medicine, National Cancer Institute (NCI) | Breast Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 08/04 | 08/04 | | |
NCT00049400: S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction |
|
|
| Completed | 1 | 78 | US | BMS-247550 | Southwest Oncology Group, National Cancer Institute (NCI) | Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 09/06 | 12/07 | | |
NCT00969046: Dose-Escalation Study in Advanced Colon Cancer Patients |
|
|
| Completed | 1 | 60 | Europe, RoW | EPO906 (patupilone) | Novartis Pharmaceuticals | Colon Cancer | 11/06 | 11/06 | | |
NCT00426140: Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies. |
|
|
| Completed | 1 | 5 | US | Patupilone | Novartis Pharmaceuticals | Advanced Malignancies, Solid Tumors | 11/06 | | | |
NCT00028561: BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors |
|
|
| Terminated | 1 | 45 | US | ixabepilone, BMS-247550, epothilone B lactam, Ixempra, carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, laboratory biomarker analysis, pharmacological study, pharmacological studies | National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 02/07 | | | |
NCT00442741: Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension) |
|
|
| Withdrawn | 1 | 0 | US | Patupilone, Patupilone + Omeprazole | Novartis Pharmaceuticals | Solid Tumors | 07/07 | | | |
NCT00412789: Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan |
|
|
| Completed | 1 | 15 | Japan | Patupilone, EPO906 | Novartis Pharmaceuticals | Tumors | 01/08 | | | |
NCT00421044: A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function |
|
|
| Completed | 1 | 14 | US | Patupilone/EPO906 | Novartis Pharmaceuticals | Advanced Malignancies, Tumors | 02/08 | | | |
NCT00448396: Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies |
|
|
| Completed | 1 | 17 | US | Patupilone | Novartis Pharmaceuticals | Advanced Malignancies | 02/08 | | | |
NCT00328458: EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients |
|
|
| Completed | 1 | 39 | US | EPO906 (epothilone B) | Sidney Kimmel Cancer Center at Thomas Jefferson University, Novartis Pharmaceuticals | Central Nervous System Neoplasms, Head and Neck Neoplasms | 05/08 | 07/09 | | |
NCT00420615: Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies |
|
|
| Completed | 1 | 34 | US | Patupilone and Omeprazole, Patupilone + Midalzolam | Novartis Pharmaceuticals | Solid Tumors | 08/08 | | | |
NCT00468260: The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies |
|
|
| Terminated | 1 | 12 | US | Patupilone | Novartis Pharmaceuticals | Advanced Malignancies | | | | |
NCT00030108: Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy |
|
|
| Completed | 1 | 30 | US | ixabepilone | National Institutes of Health Clinical Center (CC), National Cancer Institute (NCI) | Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Leukemia, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific | 03/10 | 04/10 | | |
NCT00420524: A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function |
|
|
| Completed | 1 | 36 | US | Patupilone/EPO906 | Novartis Pharmaceuticals | Advanced Malignancies, Tumors | 07/10 | | | |
NCT00426582: Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 48 | US | Patupilone | Novartis Pharmaceuticals | Advanced Solid Tumors | 08/10 | | | |
| Completed | 1 | 42 | US | Patupilone, RAD001 | University of Medicine and Dentistry of New Jersey, Novartis Pharmaceuticals, National Cancer Institute (NCI) | Refractory Malignancy | 02/11 | 02/11 | | |
NCT01084057: Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer |
|
|
| Completed | 1 | 56 | US | vorinostat, L-001079038, SAHA, suberoylanilide hydroxamic acid, Zolinza, ixabepilone, Azaepothilone B, BMS-247550, epothilone B lactam, Epothilone-B BMS 247550, Ixempra, laboratory biomarker analysis, pharmacological study, pharmacological studies | City of Hope Medical Center | Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer | 11/12 | 09/19 | | |
NCT00884676: Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors |
|
|
| Completed | 1 | 36 | US | Ixabepilone, BMS-247550, Ixempra, Azaepothilone B, epothilone B lactam, Epothilone-B BMS 247550, Sunitinib, Sunitinib Malate, Sutent, Butanedioic acid | Jaime Merchan, Bristol-Myers Squibb, Pfizer | Unspecified Adult Solid Tumor, Protocol Specific | 11/13 | 07/15 | | |
NCT01375829: Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
|
|
| Active, not recruiting | 1 | 22 | US | Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra, Pharmacological Study, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel | National Cancer Institute (NCI) | Adult Solid Neoplasm | 06/18 | 03/25 | | |
